Latest News
13January, 2020
MUNDIPHARMA ENTERS PARTNERSHIP WITH SAMSUNG BIOEPIS TO EXPAND BIOSIMILARS INTO HONG KONG AND TAIWAN
MUNDIPHARMA ENTERS PARTNERSHIP WITH SAMSUNG BIOEPIS TO EXPAND BIOSIMILARS INTO HONG KONG AND TAIWAN Singapore 13 January 2020: Mundipharma today announced a partnership with Samsung Bioepis to...
07thJanuary, 2020
MUNDIPHARMA ANNOUNCES EXCLUSIVE DEAL FOR BIOSOLUTION’S CARTILIFE® IN SOUTH KOREA
Singapore 07 January 2020: Mundipharma has announced today that it has sealed an exclusive sales agreement with Biosolution Co., Ltd, a Korea-based leader in cell-based biotechnology, to market and...
20thDecember, 2019
MUNDIPHARMA DISAGREES WITH TGA ASSESSMENT
REACTIVE STATEMENT After an extensive review of various Targin materials developed by Mundipharma Australia for Healthcare Professionals, the Therapeutic Goods Administration (TGA) issued several...
21stNovember, 2019
MUNDIPHARMA REJECTS CLAIMS IN THE ASSOCIATED PRESS STORY AND CITES INACCURACIES AND TAMPERING WITH DOCUMENTS
China, 21 November 2019: Mundipharma strongly rejects the allegations in the Associated Press story dated 20 November, that Mundipharma acted in an improper or illegal manner. Mundipharma is...
20thNovember, 2019
Response to Associated Press Story 20 November 2019
We are reviewing the claims presented in the Associated Press (AP) story dated 20 November 2019. This includes assessing the accuracy and relevance of the documents on which they base their claims. ...
03rdSeptember, 2019
VivaGel® BV regulatory approvals continue in Asia
VivaGel® BV has received a further regulatory approval in Asia Mundipharma will market VivaGel® BV under their brand name BETADINETM BV Gel in Asian countries This additional approval...
